Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
The purpose of this study is to examine the safety and tolerability of CA-18C3 in subjects with hematologic malignancies, as well as look at the preliminary efficacy of IL-1alpha blockade.
Hematologic Malignancies
DRUG: CA-18C3
Number of participants with adverse events as a measure of safety and tolerability of CA-18C3, as well as the pharmakokinetic properties of CA-18C3 in study participants., To determine the toxicities, including the dose limiting toxicity and maximum tolerated dose of CA-18C3 when administered intravenously at up to 3.75 mg/kg twice monthly in subjects with hematologic malignancies.

To determine the pharmacokinetics (PK) of CA-18C3 following study drug administration, one year
Number of participants with disease progression, stable disease, partial response or complete response of their disease while receiving CA-18C3., To observe the anti-tumor effects of CA-18C3, if any occur, One year
The purpose of this study is to examine the safety and tolerability of CA-18C3 in subjects with hematologic malignancies, as well as look at the preliminary efficacy of IL-1alpha blockade.